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ABSTRACT
Introduction: Little has been published on res-
piratory syncytial virus (RSV) among Medicare
patients at high risk (HR) of RSV complications
due to age or comorbidity.
Methods: Adult patients (at least 18 years of
age) with at least 1 diagnostic code for RSV were
identified using the 5% US Medicare database
from 2011 through 2015. Patients were required
to have continuous health plan enrollment for
180 days pre- and 180 days post-RSV diagnosis
(baseline and follow-up periods, respectively).
HR was defined as diagnosis of chronic lung
disease, congestive heart failure, or weakened
immune system for 180 days during the base-
line period. Patients were categorized as initially
hospitalized if hospitalized within 1 day of RSV
diagnosis. Logistic regression models were
developed to determine predictors of initial
hospitalization. Healthcare utilization and costs
for 180 days pre- and post-RSV diagnosis were
compared.
Results: The study included 756 HR patients
who were initially hospitalized with RSV diag-
noses. Among these, 61.7% were diagnosed in
the emergency department vs 15.3% in a
physician’s office, with hypertension (76.3%),
chronic obstructive pulmonary disease (COPD)
(53.7%), and high cholesterol (52.0%) observed
as the most prevalent comorbidities. Of these,
COPD, congestive heart failure, chronic kidney
disease, and previous evidence of pneumonia
were significant predictors of hospitalization.
Other significant predictors of hospitalization
included older age, hematological malignan-
cies, stroke, and baseline healthcare resource
use. Among both HR and non-HR hospitalized
patients, there was a significant increase in
healthcare resource utilization following hos-
pitalization, including the number of inpatient
admissions and longer hospital stays post-RSV
diagnosis. The total mean all-cause healthcare
costs among HR hospitalized patients increased
by $9210 per patient (p\0.0001) post-RSV
diagnosis.
Conclusion: Hospitalized Medicare beneficia-
ries with RSV infections pose a significant
healthcare burden as compared with non-hos-
pitalized patients, mainly driven by higher
comorbidity, higher likelihood of multiple
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inpatient admissions, and costly medical inter-
ventions.
Keywords: Infectious disease; Medicare;
Predictors of hospitalization; Respiratory
syncytial virus
Key Summary Points
Why carry out this study?
There is a gap in the literature regarding
the burden of respiratory syncytial virus
(RSV) among elderly Medicare patients
who have a high risk of RSV complications
due to age or comorbidity.
The purpose of this study was to evaluate
predictors of hospitalization and quantify
the clinical and economic burden of RSV
among Medicare patients in the USA.
What was learned from the study?
Hospitalized elderly patients with RSV had
higher associated healthcare resource
utilization, mainly driven by a higher
proportion of comorbidities, higher
likelihood of multiple inpatient
admissions, and costly medical
interventions as compared with patients
who were never hospitalized.
The study may help providers to identify
patients at highest risk for hospitalization,
morbidity, and mortality and take
appropriate measures regarding RSV
management.
INTRODUCTION
Human respiratory syncytial virus (RSV) is
common among elderly patients and can cause
lower respiratory tract infection (LRTI) includ-
ing pneumonia, exacerbate congestive heart
failure, asthma, or chronic obstructive pul-
monary disease (COPD), leading to hospitaliza-
tion [1]. According to the Centers for Disease
Control and Prevention (CDC), 177,000 hospi-
talizations yearly have been attributed to RSV
infections alone among adults aged over
65 years [2]. In general, patients aged 65 years or
older had 3–5 times higher hospitalization rates
with longer length of stay (LOS), and twice as
many emergency department (room) (ER) and
ambulatory visits compared to those aged 18–-
49 years. RSV is also the cause for LRTI in many
immunocompromised patients, such as
hematopoietic stem cell transplant (HSCT) and
solid organ transplant (SOT) recipients, includ-
ing lung transplant recipients, and those with
leukemia, lymphoma, or other cancer patients
receiving chemotherapy, and those with
advanced HIV [3].
At the time of initial presentation to a
healthcare provider, it is difficult to differenti-
ate RSV from other respiratory virus infections
on the basis of clinical parameters alone;
therefore, it is important for healthcare provi-
ders to identify the disease so that management
of RSV infection can be more effective [4].
Worldwide, no specific treatment for RSV has
received marketing authorization for use in
adults; therefore, the standard of care is sup-
portive treatment, such as intravenous fluid
hydration and oxygen supplementation. The
only treatment options with antiviral activity
are aerosolized, intravenous, or orally adminis-
tered ribavirin [5–7]. Inhaled ribavirin has lim-
ited evidence of effectiveness and carries
potential risks such as teratogenicity, bron-
chospasm, or anemia [8] for both the patient
and their care providers. While approved in
some countries for severely ill young children,
the treatment is not generally recommended in
pediatric patients [6, 9]. Ribavirin has been used
in adult patients, primarily among those who
are immunocompromised, but supporting data
are limited [10, 11].
The CDC has classified adult patients aged
65 years and older and those with chronic car-
diac or pulmonary disease or weakened immune
systems as high-risk patients who are more
likely to experience serious complications due
to RSV-related infection and have a higher risk
of mortality [12]. Elderly patients are also more
prone to RSV infections due to their decreased
immunologic response to the virus [13]. The
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morbidity, mortality, and economic burden of
RSV may therefore also be driven through the
exacerbation of underlying illness as well as the
infection itself [14, 15]. Current research on
healthcare resource utilization of RSV-related
infection focuses mainly on either pediatric or
adult patients with private healthcare insurance
[16–18]. Less has been published on healthcare
utilization and burden of disease among elderly
Medicare patients diagnosed with RSV-related
infections in the USA. To address these data
gaps, the purpose of this study was to identify
characteristics of adult RSV-infected patients in
the inpatient and outpatient setting as well as
predictors of hospitalization, and to describe
the current clinical and economic burden of




This real-world observational study was con-
ducted using the Medicare 5% national sample
administrative database from January 2011
through December 2015. All patient identifiers
in the database have been fully encrypted;
therefore, neither institutional review board
approval nor consent was necessary for this
study, as it was conducted in the USA with
depersonalized claims data and does not meet
criteria for studies with human participants; it is
therefore exempt from approval per the provi-
sion for unidentifiable personal data in the
Federal Policy for the Protection of Human
Subjects (1991).
The Medicare claims data files used for this
study included inpatient and outpatient
(Parts A and B), Medicare carrier, prescription
(Part D) drug events, skilled nursing facility
(SNF), home health agency (HHA), hospice,
durable medical equipment (DME), and the
Medicare denominator file, which contains
demographic and enrollment information of
Medicare beneficiaries.
Patient Selection
Patients with a medical claim for RSV diagnosis
(International Classification of Disease, Ninth
Revision, Clinical Modification [ICD-9-CM]
codes 079.6, 466.11, 480.01 and ICD-10-CM
codes B97.4, J20.5, J12.1, J21.0) were identified
between July 1, 2011 and June 30, 2015. The
date of the first observed RSV diagnosis during
this period was designated as the index date.
Patients were required to be aged 18 years or
older at the time of diagnosis, with continuous
Medicare medical and pharmacy benefits for at
least 180 days prior to the index date (baseline
period) and at least 180 days after the index
date (follow-up period). Patients who died dur-
ing the follow-up period were also included in
the study. Patients were excluded if they had an
RSV diagnosis during the baseline period or an
influenza or human metapneumovirus (hMPV)
diagnosis during the study period. Patients were
categorized as hospitalized if they were diag-
nosed with RSV during hospitalization or hos-
pitalized within 1 day of RSV diagnosis. The
hospital admission date was captured as the
start of the index hospitalization.
Among patients who were hospitalized, par-
ticipants were further categorized as high-risk
and non-high-risk patients. High-risk patients
were identified if they met any of the following
criteria: diagnosis of chronic lung disease (in-
cluding asthma and COPD), prior pneumonia,
congestive heart failure (CHF), or immune
compromise on or within 180 days before the
date of RSV diagnosis. A patient was considered
to be immunocompromised if they had evi-
dence of SOT, HSCT, or hematological malig-
nancies (leukemia, lymphoma, and plasma cell
neoplasms). All conditions were identified using
ICD-9-CM and ICD-10-CM codes. The non-
high-risk patients were the remaining hospital-
ized patients in the study population.
Patients were categorized as outpatients if
they were diagnosed with RSV in the outpatient
setting and not hospitalized within 1 day of
diagnosis. Patients diagnosed in the outpatient
setting were also categorized into high-risk and
non-high-risk cohorts.
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Study Variables
Baseline patient demographics including age,
sex, US geographic region, comorbidities, and
setting of diagnosis during the 180 days prior to
the index date (baseline period) were assessed
for all patients. The diagnosis setting included
ER (combined ER and/or inpatient setting),
physician’s office, or other Medicare settings
(DME, HHA, hospice, SNF). Among outpatients,
patients were further classified as later hospi-
talized (diagnosed in the outpatient setting and
hospitalized at least 2 days from index diagno-
sis) or never hospitalized. Comorbidities
including HSCT, SOT, hematological malig-
nancies, stroke, osteoporosis, anxiety, asthma,
cancer, depression, osteoarthritis, chronic kid-
ney disease (CKD), coronary artery disease
(CAD), CHF, diabetes, high cholesterol, COPD,
hypertension, and previous evidence of pneu-
monia were identified using ICD-9-CM or ICD-
10-CM codes during the baseline period
(6 months prior to the index date).
Complications, all-cause mortality, death
during inpatient stay, and 30-day readmission
rates during the follow-up period were evalu-
ated. Complications of interest—respiratory
failure, chest pain, hypoxia, cardiac arrhythmia,
cough, myocardial infarction, dyspnea, pneu-
monia, lower and upper respiratory tract infec-
tion (excluding influenza, RSV, and hMPV)—
were identified using ICD-9-CM and ICD-10-
CM codes. The proportion of patients who were
discharged to an SNF as well as LOS in an SNF
were also evaluated.
All-cause healthcare utilization and costs
during the pre- (baseline) and post-index (fol-
low-up) periods were analyzed, including hos-
pital LOS, number of office visits, pharmacy use,
ER, inpatient (and hospital LOS across all hos-
pitalization), and outpatient visits. Costs were
adjusted to 2015 US dollars using the medical
care component of the Consumer Price Index
(CPI).
Statistical Methods
All baseline and outcome variables were ana-
lyzed descriptively. Percentages and counts
were provided for categorical variables. Means
and standard deviations (SDs) were computed
for continuous variables. Healthcare costs and
utilizations were analyzed descriptively and
compared between 180 days pre- and post-RSV
diagnosis. Bivariate comparison between pre-
and post-index date periods were made using a
paired t test to evaluate the statistical signifi-
cance for continuous variables, including aver-
age number of resource utilization and costs.
Multivariate logistic regression was con-
ducted to examine potential predictors of hos-
pitalization among hospitalized patients vs
those who were never hospitalized. Purposeful
model selection was used to identify variables to
be included in the logistic regression. First, all
independent variables with p\ 0.25 in bivariate
testing were initially included in the model.
Secondly, variables with p[ 0.10 were dropped
from the model sequentially unless they were
identified as confounders (i.e., variables that,
when dropped from the model, resulted in at
least a 20% change in parameter estimates for 1
or more of the other variables, when compared
to the original model). The final model included
confounders, variables that had p B 0.10, and
high-risk conditions. Covariates in the final
model included demographics, comorbidities,
previous evidence of pneumonia, number of
conditions, and the number of inpatient and ER
visits during the baseline period.
Statistical analyses were conducted using the
Statistical Analysis System (SAS) v.9.3. (Cary,
North Carolina, USA). The threshold for p value
significance was set at a-level 0.05 for pre–post
analysis and logistic regression.
RESULTS
Patient Population
A total of 3510 patients diagnosed with RSV
were identified from the Medicare 5% national
sample administrative database. Figure 1 shows
the selection criteria to identify patients with
RSV. After the inclusion and exclusion criteria
were applied, the final analytical sample com-
prised 1795 patients, including 793 (44.2%)
patients who were hospitalized (within 1 day of
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RSV diagnosis), 835 (46.5%) diagnosed in the
outpatient setting (not hospitalized within
1 day of RSV diagnosis), and 167 (9.3%) diag-
nosed in other Medicare settings (DME, HHA,
hospice, SNF). The study population included
756 (42.1%) high-risk patients who were ini-
tially hospitalized and 37 (2.1%) non-high-risk
patients who were hospitalized. Among patients
diagnosed in the outpatient setting, 399
(47.8%) were classified as high-risk patients,
whereas 436 (52.2%) were classified as non-
high-risk patients. Among patients diagnosed in
the outpatient setting, 140 (16.8%) were later
hospitalized (i.e., hospitalized after 1 day of RSV
diagnosis) and 695 (83.2%) of patients were
never hospitalized during the follow-up period
(Fig. 1).
Baseline Characteristics
Patient characteristics and diagnosis setting are
summarized in Table 1. Among hospitalized high-
risk patients, 61.7% were diagnosed in the ER
setting, whereas 15.3% and 23.0% were diag-
nosed in a physician’s office or other Medicare
settings, respectively. On average, high-risk
hospitalized patients were older (mean age
77 years; SD 13.4 years) than those who were
not hospitalized (mean age 74 years; SD
14.5 years). Most of the total sample population
were female patients residing in the southern
US region. Of high-risk patients initially hospi-
talized, hypertension (76.3%), COPD (53.7%),
high cholesterol (52.0%), diabetes (41.1%), CHF
(41.1%), CAD (39.8%), CKD (31.0%), and pre-
vious evidence of pneumonia (42.3%) were
Fig. 1 Flow chart for patient inclusion criteria. HR high
risk, hMPV human metapneumovirus, ICU intensive care
unit, MV mechanical ventilation, RSV respiratory syncytial
virus. aThe total study cohort includes patients diagnosed
in inpatient, outpatient, or other Medicare settings.
bPatients who did not use services in the ICU or MV
during the index hospitalization. cPatients who used
services in the ICU during index hospitalization; ICU
and MV are not mutually exclusive. dPatients who used
MV during index hospitalization; ICU and MV are not
mutually exclusive. ePatients who used supplemental
oxygen during index hospitalization
Adv Ther (2020) 37:1203–1217 1207









N = 756 N = 37 N = 399 N = 436
Age, mean (SD) 77.1 (13.4) 71.9 (17.1) 73.6 (14.5) 71.1 (12.3)
Age group (years), n (%)
\ 65 112 (14.8%) 11 (29.7%) 83 (20.8%) 93 (21.3%)
65–74 167 (22.1%) 8 (21.6%) 111 (27.8%) 177 (40.6%)
75–84 222 (29.4%) 10 (27.0%) 107 (26.8%) 111 (25.5%)
C 85 255 (33.7%) 8 (21.6%) 98 (24.6%) 55 (12.6%)
Sex, n (%)
Male 267 (35.3%) 9 (24.3%) 123 (30.8%) 164 (37.6%)
Female 489 (64.7%) 28 (75.7%) 276 (69.2%) 272 (62.4%)
US geographic region, n (%)
Northeast 221 (29.2%) 11 (29.7%) 94 (23.6%) 126 (28.9%)
North central 189 (25.0%) 9 (24.3%) 82 (20.6%) 73 (16.7%)
South 264 (34.9%) 10 (27.0%) 143 (35.8%) 145 (33.3%)
West 80 (10.6%) 7 (18.9%) 72 (18.0%) 89 (20.4%)
Unknown 2 (0.3%) 0 (0.0%) 8 (2.0%) 3 (0.7%)
Diagnosis setting, n (%)
ER settingb 466 (61.7%) 37 (100.0%) 35 (8.8%) 9 (2.1%)
Outpatient setting 116 (15.3%) 0 (0.0%) 364 (91.2%) 427 (97.9%)
Other settingsc 174 (23.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Comorbidities, n (%)
Anxiety 131 (17.3%) 7 (18.9%) 44 (11.0%) 17 (3.9%)
Asthma 139 (18.4%) 0 (0.0%) 97 (24.3%) 0 (0.0%)
Cancer 147 (19.4%) 10 (27.0%) 54 (13.5%) 34 (7.8%)
Chronic obstructive pulmonary disease 406 (53.7%) 0 (0.0%) 253 (63.4%) 0 (0.0%)
Congestive heart failure 311 (41.1%) 0 (0.0%) 109 (27.3%) 0 (0.0%)
Coronary artery disease 301 (39.8%) 6 (16.2%) 102 (25.6%) 62 (14.2%)
Depression 200 (26.5%) 7 (18.9%) 79 (19.8%) 36 (8.3%)
Diabetes 311 (41.1%) 12 (32.4%) 142 (35.6%) 123 (28.2%)
High cholesterol 393 (52.0%) 17 (45.9%) 204 (51.1%) 173 (39.7%)
Hypertension 577 (76.3%) 19 (51.4%) 273 (68.4%) 217 (49.8%)
Chronic kidney disease 234 (31.0%) 10 (27.0%) 46 (11.5%) 12 (2.8%)
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among the most prevalent comorbid conditions
during the baseline period. These conditions
were also the most common comorbidities
occurring among high-risk patients in the out-
patient cohort (Table 1).
Predictors of Initial Hospitalization
Figure 2 shows predictors of hospitalization
using a logistic regression model. Comorbidities
such as hematological malignancies (odds ratio
[OR] 5.17; p\0.001), CKD (OR 4.37; p\0.001),
COPD (OR 2.12; p\ 0.001), CHF (OR 2.06;
p = 0.002), and stroke (OR 2.00; p = 0.045) as
well as previous evidence of pneumonia (OR
2.79; p\0.001) were significant predictors of
hospitalization, after adjusting for other
covariates. Other significant predictors of hos-
pitalization included older age and healthcare
resource use during the baseline period (Fig. 2).
Outcomes Assessment
Figure 3 illustrates outcomes of patients with
RSV during the follow-up period. During the
180 days post-RSV diagnosis, upper and lower
respiratory tract infections (88.1% excluding
influenza, RSV, and hMPV), pneumonia
(77.2%), dyspnea (74.7%), and arrhythmias
(51.1%) were predominant complications
among high-risk hospitalized patients. These
conditions were also the most common com-
plications among hospitalized non-high-risk
patients and high-risk outpatients. The com-
plication rates were much lower in non-high-
risk outpatients (Fig. 3).
Outcomes are described in Table 2. Mortality
and readmission rates were highest in the high-
risk hospitalized patients (Table 2). Deaths dur-
ing inpatient stay (hospitalization) occurred
among 4.2% of the high-risk hospitalized
patients and 0% among hospitalized non-high-
risk patients. The all-cause mortality within
30 days of RSV diagnosis was 13.4% among high-
risk hospitalized patients and 8.1% among hos-
pitalized non-high-risk patients. Among high-
risk patients discharged from a hospital, 24.7%
were discharged to an SNF with a mean LOS of
7.8 days; of those, 71.1% did not reside in an SNF
prior to hospitalization, whereas 13.5% of hos-
pitalized non-high-risk patients were discharged
to an SNFwith ameanLOSof 5.1 days and80%of
those did not utilize an SNF prior to hospitaliza-
tion. The 30-day hospital readmission rate was
20.4% and 16.2% for hospitalized high-risk and










N = 756 N = 37 N = 399 N = 436
Osteoarthritis 219 (29.0%) 8 (21.6%) 110 (27.6%) 71 (16.3%)
Osteoporosis 100 (13.2%) 1 (2.7%) 39 (9.8%) 46 (10.6%)
Stroke 82 (10.8%) 1 (2.7%) 18 (4.5%) 9 (2.1%)
Hematological malignancies 54 (7.1%) 0 (0%) 10 (2.2%) 0 (0%)
Solid organ transplant 40 (5.3%) 0 (0%) 5 (1.3%) 0 (0%)
Stem cell transplant 10 (1.3%) 0 (0%) 1 (0.3%) 0 (0%)
Previous evidence of pneumonia, n (%) 320 (42.3%) 0 (0.0%) 95 (23.8%) 0 (0.0%)
COPD chronic obstructive pulmonary disease, ER emergency room
a See ‘‘Methods’’ and ‘‘Patient Selection’’ for high-risk criteria
b ER includes patients diagnosed in inpatient and ER settings
c Other settings includes durable medical equipment (DME), home health agency (HHA), hospice, and skilled nursing
facility (SNF)
Adv Ther (2020) 37:1203–1217 1209
Pre–Post Analysis
Table 3 depicts pre- and post-RSV diagnosis
analysis of healthcare resource utilization and
costs among high-risk and non-high-risk hos-
pitalized patients as well as outpatients. Among
HR hospitalized patients, significant increases
in the number of inpatient visits (from 1.2 to
1.5 visits; p\0.001) and longer LOS (from 9.0
to 12.2 days; p\0.001) were observed across all
hospitalizations (including the index hospital-
ization), whereas the number of outpatient
visits decreased post-RSV diagnosis (from 17.8
to 15.2 visits; p\0.001), along with pharmacy
Fig. 2 Predictors of initial hospitalization. CI confidence
interval, COPD chronic obstructive pulmonary disease, ER
emergency room, OR odds ratio. aThe following were used
as references: age (\ 65 years), sex (male), US geographic
region (northeast), number of comorbidities (n = 0),
number of inpatient visits (n = 0). bVariables were
evaluated during the baseline period. cOR[ 1 indicates
that the variable is a positive predictor of hospitalization
among patients who were initially hospitalized (N = 793)
as compared with patients who were never hospitalized
(N = 695)
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visits (from 21.1 to 16.0 visit; p\0.001). Simi-
larly, hospitalized non-high-risk outpatients
incurred an increased number of inpatient visits
(from 0.6 to 1.9 visits; p\0.001) and prolonged
LOS (from 3.1 days to 11.4 days; p\ 0.001) fol-
lowing the RSV diagnosis.
A significant difference in healthcare visits
was not observed between the pre- and post-RSV
diagnosis period among high-risk outpatients.
However, as compared with the pre-RSV diag-
nosis period, incremental increases in the
number of inpatient (from 0.1 to 0.2;
p = 0.028), outpatient (from 10.8 to 12.3;
p\0.001), and pharmacy visits (from 11.9 to
12.6; p = 0.029) were observed post-RSV diag-
nosis among non-high-risk outpatients.
Total average per patient all-cause healthcare
costs increased by $9210 (p\0.001) for high-
risk hospitalized patients, $19,141 (p\ 0.001)
for hospitalized non-high-risk patients, and
$2072 (p\0.001) for non-high-risk outpatients.
Total average per patient all-cause healthcare
costs were similar ($1610) for high-risk outpa-
tients (p = 0.252). The primary cost drivers were
related to all-cause hospitalization costs, which
increased for hospitalized high-risk patients
(from $16,604 to $23,172; p\ 0.001), hospital-
ized non-high-risk patients (from $6365 to
$21,810; p\0.001), and outpatient non-high-
risk patients (from $922 to $1940; p = 0.009)
during the follow-up period (Table 3).
DISCUSSION
To our knowledge, this is the first study to
identify characteristics of adult patients with
RSV in the inpatient and outpatient setting and
Fig. 3 Complications during the follow-up period among
patients with RSV. COPD chronic obstructive pulmonary
disease, HR high risk, RTI respiratory tract infection.
aExcluding influenza, RSV, and hMPV. bSee ‘‘Methods’’
and ‘‘Patient Selection’’ for high-risk criteria
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predictors of hospitalization as well as to
describe the current clinical and economic
burden of RSV in the US Medicare population.
Our study demonstrates that hematological
malignancies, number of inpatient visits prior
to hospitalization for RSV and chronic kidney
disease (CKD), previous evidence of pneumonia
(during the baseline period), congestive heart
failure (CHF), stroke, and older age were among
the predictors of hospitalization. All-cause
mortality among high-risk hospitalized patients
was 4.2% during inpatient stays and 13.4%
within 30 days of diagnosis. Among high-risk
and non-high-risk hospitalized patients, there
was a significant increase in healthcare resource
utilization including the number of subsequent
inpatient admissions and longer hospital stays
post-RSV diagnosis, as compared with non-
hospitalized patients. The total mean all-cause
healthcare costs among high-risk hospitalized
and non-high-risk hospitalized patients
increased by $9210 (p\ 0.0001) per patient and
$19,141 (p\0.001) per patient post-RSV diag-
nosis, respectively.
RSV leads to in significant morbidity and
mortality, with 14,000 reported deaths, and
more than 177,000 hospitalizations annually in
the USA among adults 65 years of age and older
[2]. In addition, elderly patients with underly-
ing high-risk conditions are prone to compli-
cations related to LRTIs, resulting in prolonged
hospitalization, and therefore potentially death
[15, 19, 20]. Although RSV typically presents
with mild cold-like symptoms, RSV can some-
times lead to more severe complications
including LRTI, pneumonia, and exacerbation
of underlying conditions such as CHF, asthma,
and COPD [21–25]. Similarly, most hospitalized
high-risk patients in our study were older (av-
erage age 77 years) and diagnosed with LRTI
(84.3%, excluding influenza, RSV, or hMPV),
and had previous evidence of pneumonia
Table 2 Descriptive outcomes assessment for patients diagnosed with RSV
Hospitalized high-riska Hospitalized non-high-risk
N = 756 N = 37
Length of stay during initial hospitalization, mean (SD) 7.0 (10.7) 5.5 (4.6)
30-day readmission, N (%) 154 (20.4%) 6 (16.2%)
Patients who were discharged to SNF, N (%) 187 (24.7%) 5 (13.5%)
% of patients not in SNF prior to hospitalization 133 (71.1%) 4 (80.0%)
% of patients in SNF prior to hospitalization 54 (28.9%) 1 (20.0%)
Length of stay in skilled nursing facility, mean (SD) 7.8 (32.2) 5.1 (17.9)
All-cause mortality, N (%)
Within 30 days of RSV diagnosis 101 (13.4%) 3 (8.1%)
Within 90 days of RSV diagnosis 178 (23.5%) 3 (8.1%)
Within 180 days of RSV diagnosis 221 (29.2%) 4 (10.8%)
Death during inpatient stay, N (%)
Within 30 days of RSV diagnosis 32 (4.2%) 0 (0.0%)
Within 90 days of RSV diagnosis 57 (7.5%) 0 (0.0%)
Within 180 days of RSV diagnosis 69 (9.1%) 1 (2.7%)
RSV respiratory syncytial virus, SD standard deviation, SNF skilled nursing facility
a See ‘‘Methods’’ and ‘‘Patient Selection’’ for high-risk criteria
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Table 3 Pre- and post-RSV diagnosis healthcare costs and utilization among Medicare patients with RSV
Hospitalized high-riska, N = 756 Hospitalized non-high-risk, N = 37
Pre-index Post-index p valueb Pre-index Post-index p valueb












21.1 (14.7) 16.0 (14.1) \ 0.0001* 15.5 (11.6) 12.8 (8.8) 0.149
Length of
stay
9.0 (15.0) 12.2 (19.2) \ 0.0001* 3.1 (7.9) 11.4 (16.5) 0.000*
All-cause healthcare costs mean (SD)
Outpatient
costs
$6540 ($10,783) $5544 ($10,113) 0.003* $5421 ($0) $3924 ($4619) 0.252
Inpatient
costs
$16,604 ($27,664) $23,172 ($33,438) \ 0.0001* $6365 ($14,828) $21,810 ($26,005) 0.000*
Pharmacy
costs
$3776 ($6834) $3002 ($6445) \ 0.0001* $1678 ($2244) $1605 ($2140) 0.760
Other costsc $4793 ($10,434) $9205 ($13,619) \ 0.0001* $3598 ($11,849) $8866 ($16,311) 0.062
Total costsd $31,713 ($36,718) $40,923 ($41,152) \ 0.0001* $17,063 ($27,446) $36,204 ($32,597) 0.000*
Outpatient high-risk, N = 399 Outpatient non-high-risk, N = 436
Pre-index Post-index p valueb Pre-index Post-index p valueb
All-cause healthcare utilization mean (SD)
# of inpatient visits 0.5 (0.9) 0.5 (1.0) 0.967 0.1 (0.4) 0.2 (0.5) 0.028*
# of outpatient visit 15.9 (11.8) 16.6 (11.1) 0.170 10.8 (10.0) 12.3 (9.7) \ 0.0001*
# of pharmacy uses 17.3 (11.3) 18.1 (12.2) 0.110 11.9 (10.0) 12.6 (9.2) 0.029*
Length of stay 3.0 (8.5) 3.1 (10.0) 0.868 0.5 (2.9) 0.9 (3.6) 0.052
All-cause healthcare costs mean (SD)
Outpatient costs $3886 ($5534) $3891 ($4888) 0.987 $2452 ($4436) $2836 ($4603) 0.056
Inpatient costs $5648 ($15,138) $5874 ($16,425) 0.831 $922 ($4221) $1940 ($7027) 0.009*
Pharmacy costs $2454 ($3590) $2777 ($6408) 0.225 $2036 ($4138) $2314 ($5708) 0.260
Other costsc $2510 ($6686) $3567 ($8856) 0.020* $437 ($2250) $829 ($3628) 0.030*
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(77.2%), dyspnea (74.7%), or COPD (65.5%) in
the 180 days pre-RSV infection, which may
have been caused by secondary RSV-related
complications.
Most available research on the economic
burden of RSV in the USA predominantly
focuses on infants or adult patients in private
insurance populations that largely comprise
patients less than 65 years of age. These studies
highlight the increased burden of RSV due to
the higher utilization of healthcare resources
including intensive care and ventilator support,
and the costs incurred as a result of underlying
conditions [26]. In a study by Han et al., the
annual total costs related to RSV pneumonia
hospitalization in all elderly patients aged
65 years and older were estimated in the range
of $150–680 million [27]. Pastula et al. also
indicated that the average hospitalization costs
associated with RSV infection among all adults
in the USA were $38,828 [28]. Amand et al.
found that the incremental differences in
adjusted annual healthcare costs between
patients with and without RSV was higher
among patients aged 65 years and older
($12,030–23,194) than among those aged less
than 65 years old ($2251–5391) [18]. The cur-
rent analysis observed significant increases in
medical resource utilization after RSV diagnosis,
including an increase in the number of subse-
quent inpatient admissions and prolonged
hospital LOS among high-risk hospitalized
patients. The higher resource utilization
observed in this study also translated to
increased healthcare costs. Total mean all-cause
healthcare costs per patient increased by $9210
per patient (p\ 0.0001) for high-risk hospital-
ized patients, $19,141 (p\0.001) for hospital-
ized non-high-risk patients, and $2072
(p\ 0.001) for non-high-risk outpatients from
the baseline period to the follow-up period,
while hospitalization costs were the main cost
driver (57%). This is consistent Amand et al.’s
findings that patients 65 years of age and older
had 3–5 times more hospitalizations as com-
pared with those aged 18–49 years.
ER visits, hospitalizations, ICU admissions,
and death due to respiratory complications play
an important role in the clinical burden of RSV
infection. Emergency departments are espe-
cially likely to be the first point of care for
patients with RSV. Overall, 4.2% of the admit-
ted high-risk patients died during an inpatient
stay and 13.4% within 30 days of diagnosis. At
discharge, 24.7% of the admitted high-risk
patients in the current study were discharged to
an SNF where they remained on average for
7.8 days. Among high-risk patients discharged
to an SNF, 71.1% did not reside in an SNF prior
to hospitalization. The burden of an RSV out-
break is high in long-term care facilities such as
SNFs [29].
Despite the substantial disease burden, the
importance of RSV may not be recognized by
admitting physicians, and RSV management
may not be initiated promptly. This may impact
health outcomes among elderly patients,
increasing the burden of their disease. Rapid
identification of RSV may influence decision-
making for treatment, which in turn can
Table 3 continued
Outpatient high-risk, N = 399 Outpatient non-high-risk, N = 436
Pre-index Post-index p valueb Pre-index Post-index p valueb
Total costsd $14,498 ($21,611) $16,108 ($23,688) 0.252 $5847 ($9090) $7919 ($12,976) 0.000*
RSV respiratory syncytial virus, SD standard deviation
*p B 0.05
a See ‘‘Methods’’ and ‘‘Patient Selection’’ for high-risk criteria
b p values were calculated using paired t tests
c Other costs includes durable medical equipment (DME), home health agency (HHA), hospice, and skilled nursing facility
(SNF)
d Total costs consists of the sum of inpatient costs, outpatient costs, pharmacy costs, and other costs
1214 Adv Ther (2020) 37:1203–1217
optimize effective patient management, thereby
reducing hospital admission rates and LOS
[30–32]. Rapid molecular tests for viral patho-
gen detection have been shown to decrease
hospital LOS [32]. It is important for attending
physicians to identify patients with RSV who
require more than the current standard of care
at the time of diagnosis. The results of this study
demonstrate that hematological malignancies,
the number of inpatient visits, CKD, pneumo-
nia, CHF, CAD, stroke, and older age were pre-
dictors of hospitalizations, which may help
healthcare providers to treat high-risk patients
more effectively.
Limitations
Certain limitations should be acknowledged
regarding the results of this study. As with all
retrospective claims analyses, the study utilized
claims data that were primarily coded for
administrative purposes rather than clinical
accuracy, and was therefore susceptible to cod-
ing errors and diagnosis discrepancies. In claims
database analysis, only associations rather than
casual inferences can be inferred.
In this study specifically, the RSV diagnosis
was captured on the basis of ICD-9/10-CM
codes and not diagnostic testing. This method-
ology may have led to the underestimation or
overestimation of the actual number of RSV
cases, as there could be an inherent difficulty of
distinguishing between RSV and RSV-like ill-
ness, although we did exclude patients with
influenza and hMPV to get a more exclusive
sample of patients with RSV. Complications
were identified as conditions that occurred
6 months following an RSV diagnosis date (ICD-
9/ICD-10 codes); therefore, we could not ascer-
tain whether the conditions were an actual
complication of RSV or a progression of an
underlying disease that may have been exacer-
bated as a result of RSV. In addition, RSV com-
plications related to the disease progression or
exacerbation of underlying chronic conditions
such as COPD or CHF were not captured
because of the lack of relevant diagnostic codes
in the data. Therefore, we might have underes-
timated the rate of complications in this
population. We also could not distinguish
between community-acquired and hospital-ac-
quired RSV infection because of lack of ICD
codes to differentiate between 2 settings.
Moreover, this study used a fee-for-service (FFS)
Medicare database that includes information on
Medicare FFS beneficiaries only (approx. 69% of
Medicare beneficiaries in 2015) [33], which may
limit the generalizability of the study results to
patients with commercial insurance plans.
CONCLUSION
Hospitalized Medicare beneficiaries with RSV
infections pose a substantial burden on the
healthcare system, primarily due to comorbidi-
ties that require more intensive management
related to RSV-mediated exacerbations, a higher
likelihood of multiple inpatient admissions,
and costly medical interventions, such as ICU
admission and/or mechanical ventilation.
Emergency departments and general wards are
likely to be the first point of care for these
patients. This study demonstrates a significant
burden of RSV among elderly patients that is
consistent with existing literature. The incre-
mental all-cause total healthcare costs were
estimated at $9210 post-RSV diagnosis, com-
pared to pre-RSV diagnosis, for high-risk hospi-
talized patients.
RSV-infected elderly patients with high-risk
underlying conditions experience greater mor-
bidity and generate a substantial economic
burden to the healthcare system. The findings
from this research may help policymakers,
healthcare providers, and other stakeholders in
identifying patients at highest risk for hospi-
talization, morbidity, and mortality, so as to
make more informed decisions regarding RSV
management.
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